Type 2 DiabetesPROMOTENCT07181304
Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes
A study testing PROMOTE and DSMES in people with Type 2 Diabetes, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
This study will include a type 1 hybrid effectiveness implementation study to evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes recruited from local primary care practices in Jefferson County, Alabama. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- PROMOTE and DSMES
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Nov 2026to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 19 years or older
- Black race (self-reported)
- Diagnosis of type 2 diabetes
- Uncontrolled A1C >8%
- Receipt of care at one of the study sites
- Speaks and reads in English
Who cannot join
- Limited English proficiency
- Currently pregnancy
- Non-community dwelling.
- Speaks and reads in English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Cooper Green Mercy Health System
Birmingham, Alabama, 35294
Raegan Durant, MD, (205) 930-3200, rdurant@uabmc.edu
About this study
Official title: Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes: PROMOTE Study
This study will include a type 1 hybrid effectiveness implementation study to evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes recruited from local primary care practices in Jefferson County, Alabama. Additionally, a mixed methods evaluation to characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) will be conducted.
Read the detailed description
In the proposed study, the study team will conduct a type 1 hybrid effectiveness-implementation randomized controlled trial (RCT) of peer support plus remote patient monitoring as well as a mixed methods evaluation of contextual factors relevant to program delivery and implementation. Black adults with uncontrolled type 2 diabetes (A1C >8%) from primary care practices in Jefferson County, Alabama will be recruited to participate in this RCT.
Specific Aim 1: To evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes in Jefferson County, Alabama. Hypothesis: The PROMOTE program will be effective, leading to clinically meaningful improvements in glycemic control.
A type 1 hybrid effectiveness-implementation RCT among Black adults with uncontrolled type 2 diabetes (A1C >8%) will test the PROMOTE program. The study team will be working with primary care practices in Jefferson County, Alabama through a consortium of community-based primary care providers who aim to improve healthcare delivery and outcomes by integrating research into their daily practice of medicine. Participants will be randomized 1:1 to intervention (PROMOTE) or control condition. Both study arms will receive diabetes self-management education and support (DSMES) delivered virtually. Participants randomized to the PROMOTE program will receive core components of peer support, remote patient monitoring of blood glucose, and integration with clinical care. Peer support will be delivered by trained ConnectionHealth CHWs with an initial in-person visit, followed by phone visits weekly for 3 months, then monthly for 3 months. ConnectionHealth is a 501c3 nonprofit organization that was founded in December 2014 in Birmingham, Alabama dedicated to training and deploying community health workers (CHWs) to address the needs of Alabama's most vulnerable citizens. Currently, ConnectionHealth serves citizens in Jefferson County, Shelby County, and the Black Belt Region of rural Alabama, providing community-based support with the goal of assisting clients to achieve healthier lives. The study team will partner with UAB eMedicine to deliver remote patient monitoring program. UAB eMedicine has an active remote patient monitoring program that is currently monitoring over 900 patients. All glucose values are transmitted via cellular enabled devices; the patients do not need access to their own internet plan or to their own smart device, which ensures that there are no disparities related to the technology. Furthermore, test strips are provided to patients on a regular basis by the program based on the number of readings performed, which eliminates a barrier of cost. Participants will be asked to check blood glucose with remote patient monitoring daily for 6 months, frequency tailored to their medication regimen. Monthly reports of peer support and remote patient monitoring activities will be provided to primary care providers. Clinical and patient-reported outcomes will include change from baseline to 6 months for the following: A1C (primary), as well as secondary outcomes of blood pressure, low density lipoprotein levels, body mass index, diabetes self-management, and diabetes distress. Clinical outcome will be extracted from the electronic health record and patient reported outcomes will be obtained via patient survey using validated measures. The main analysis will used linear mixed effects models to model change in each outcome (e.g. A1C) by study group (intervention vs. control arms), adjusted for the baseline value, accounting for any meaningful clustering using random intercepts. The hypotheses of an intervention effect will be tested by the significance of the coefficient for study group at the p<0.05 level.
Specific Aim 2: To characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) through mixed methods evaluation.
PRISM is a context-oriented framework that aligns well with this study because it is intended to be used across program phases from pre-implementation, implementation, evaluation, and sustainment phases with a focus on the contextual domains closely tied to the outcomes of the RE-AIM framework (Reach Effectiveness Adoption Implementation and Maintenance). The study team will use purposeful recruitment to identify provider participants with a goal of 2-4 key informant provider participants per site with the following roles represented including physicians and advanced practice providers, nurses, care coordinators, and administrative staff. The study team will use parallel convergent mixed methods utilizing PRISM to assess perspectives and characteristics at the organizational and patient levels, as well as implementation and sustainability infrastructure and external environment, to determine key contextual factors that serve as implementation determinants.23 These results will be applied to determine future implementation strategies.
- Conditions
- Type 2 Diabetes
- Being tested
- PROMOTE, DSMES
- Keywords
- Peer support, Remote patient monitoring
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PROMOTEBehavioural
PROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care.
- Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months.
- RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F.
- A monthly report of peer support activities and RPM data will be sent to participants' primary care providers.
DSMESBehavioural
Diabetes Self-Management Education and Support delivered virtually.
| Study group | Role | What they receive |
|---|---|---|
| PROMOTE | Experimental | Not described Receives: Behavioral: PROMOTE; Behavioral: DSMES |
| Control | Active comparator | Not described Receives: Behavioral: DSMES |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Hemoglobin A1c (A1C)
Change in A1C value at 6-months compared to baseline. Lab values will be extracted from electronic health record. Per the American Diabetes Association (ADA) Standards of Care, A1C is recommended to be checked quarterly for patients with type 2 diabetes, whose A1C is not at target level (i.e. the eligibility criteria for this study sample).
Measured: Baseline, 6-months
Secondary outcomes (3)
Change in blood pressure
Biometric data will be extracted from electronic health record by study personnel. Blood pressure is recommended to be checked at each followup visit for patients with type 2 diabetes; recommended follow-up visit frequency of every 3 months for patients whose A1C is not at the target level.
Measured: Baseline, 6-months
Change in Low Density Lipoprotein (LDL)
Laboratory data will be extracted from electronic health record by study personnel. Per the American Diabetes Association (ADA) Standards of Care, LDL is recommended to be checked annually for patients with type 2 diabetes
Measured: Baseline, 6-months
Change in Body Mass Index (BMI)
Biometric data will be extracted from electronic health record by study personnel. BMI is recommended to be measured at each followup visit for patients with type 2 diabetes; recommended follow-up visit frequency of every 3 months for patients whose A1C is not at the target level.
Measured: Baseline, 6-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2025
- Study start30 Nov 2026 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Collaborators
- American Diabetes Association
- Responsible party
- Principal investigator, Caroline Presley, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07181304
- Sponsor's protocol ID
- IRB-300015327
- Other IDs
- 7-25-ICTSPC-410
- Acronym
- PROMOTE
- Status last verified
- Oct 2026
- First submitted
- 11 Sep 2025
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified Individual Participant Data for the following measures will be restricted with a data use agreement: 1) Biometric and lab data including hemoglobin A1c, height, weight, body mass index, blood pressure, remote monitoring of blood glucose; 2) Demographics and health status per NIH required common data elements; 3) Survey assessment: Diabetes Distress Scale, Patient Health Questionnaire, Diabetes Self-Management Questionnaire, Diabetes Self-Efficacy, and Social Support
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes: PROMOTE Study
- ClinicalTrials.gov ID
- NCT07181304
- Acronym / sponsor ID
- PROMOTE / IRB-300015327
- Conditions
- Type 2 Diabetes
- Keywords
- Peer support, Remote patient monitoring
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Collaborators
- American Diabetes Association
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 18 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will include a type 1 hybrid effectiveness implementation study to evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes recruited from local primary care practices in Jefferson County, Alabama. Additionally, a mixed methods evaluation to characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) will be conducted.
Detailed description
In the proposed study, the study team will conduct a type 1 hybrid effectiveness-implementation randomized controlled trial (RCT) of peer support plus remote patient monitoring as well as a mixed methods evaluation of contextual factors relevant to program delivery and implementation. Black adults with uncontrolled type 2 diabetes (A1C >8%) from primary care practices in Jefferson County, Alabama will be recruited to participate in this RCT.
Specific Aim 1: To evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes in Jefferson County, Alabama. Hypothesis: The PROMOTE program will be effective, leading to clinically meaningful improvements in glycemic control.
A type 1 hybrid effectiveness-implementation RCT among Black adults with uncontrolled type 2 diabetes (A1C >8%) will test the PROMOTE program. The study team will be working with primary care practices in Jefferson County, Alabama through a consortium of community-based primary care providers who aim to improve healthcare delivery and outcomes by integrating research into their daily practice of medicine. Participants will be randomized 1:1 to intervention (PROMOTE) or control condition. Both study arms will receive diabetes self-management education and support (DSMES) delivered virtually. Participants randomized to the PROMOTE program will receive core components of peer support, remote patient monitoring of blood glucose, and integration with clinical care. Peer support will be delivered by trained ConnectionHealth CHWs with an initial in-person visit, followed by phone visits weekly for 3 months, then monthly for 3 months. ConnectionHealth is a 501c3 nonprofit organization that was founded in December 2014 in Birmingham, Alabama dedicated to training and deploying community health workers (CHWs) to address the needs of Alabama's most vulnerable citizens. Currently, ConnectionHealth serves citizens in Jefferson County, Shelby County, and the Black Belt Region of rural Alabama, providing community-based support with the goal of assisting clients to achieve healthier lives. The study team will partner with UAB eMedicine to deliver remote patient monitoring program. UAB eMedicine has an active remote patient monitoring program that is currently monitoring over 900 patients. All glucose values are transmitted via cellular enabled devices; the patients do not need access to their own internet plan or to their own smart device, which ensures that there are no disparities related to the technology. Furthermore, test strips are provided to patients on a regular basis by the program based on the number of readings performed, which eliminates a barrier of cost. Participants will be asked to check blood glucose with remote patient monitoring daily for 6 months, frequency tailored to their medication regimen. Monthly reports of peer support and remote patient monitoring activities will be provided to primary care providers. Clinical and patient-reported outcomes will include change from baseline to 6 months for the following: A1C (primary), as well as secondary outcomes of blood pressure, low density lipoprotein levels, body mass index, diabetes self-management, and diabetes distress. Clinical outcome will be extracted from the electronic health record and patient reported outcomes will be obtained via patient survey using validated measures. The main analysis will used linear mixed effects models to model change in each outcome (e.g. A1C) by study group (intervention vs. control arms), adjusted for the baseline value, accounting for any meaningful clustering using random intercepts. The hypotheses of an intervention effect will be tested by the significance of the coefficient for study group at the p<0.05 level.
Specific Aim 2: To characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) through mixed methods evaluation.
PRISM is a context-oriented framework that aligns well with this study because it is intended to be used across program phases from pre-implementation, implementation, evaluation, and sustainment phases with a focus on the contextual domains closely tied to the outcomes of the RE-AIM framework (Reach Effectiveness Adoption Implementation and Maintenance). The study team will use purposeful recruitment to identify provider participants with a goal of 2-4 key informant provider participants per site with the following roles represented including physicians and advanced practice providers, nurses, care coordinators, and administrative staff. The study team will use parallel convergent mixed methods utilizing PRISM to assess perspectives and characteristics at the organizational and patient levels, as well as implementation and sustainability infrastructure and external environment, to determine key contextual factors that serve as implementation determinants.23 These results will be applied to determine future implementation strategies.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PROMOTE | Experimental | Behavioral: PROMOTE, Behavioral: DSMES |
| Control | Active comparator | Behavioral: DSMES |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 19 years or older
- Black race (self-reported)
- Diagnosis of type 2 diabetes
- Uncontrolled A1C >8%
- Receipt of care at one of the study sites
Key exclusion criteria (4 listed)
- Limited English proficiency
- Currently pregnancy
- Non-community dwelling.
- Speaks and reads in English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PROMOTEPROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care. 1. Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months. 2. RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F. 3. A monthly report of peer support activities and RPM data will be sent to participants' primary care providers. | Behavioural | PROMOTE |
| DSMESDiabetes Self-Management Education and Support delivered virtually. | Behavioural | Control, PROMOTE |
Primary outcome
Change in Hemoglobin A1c (A1C)
Time frame: Baseline, 6-months
Change in A1C value at 6-months compared to baseline. Lab values will be extracted from electronic health record. Per the American Diabetes Association (ADA) Standards of Care, A1C is recommended to be checked quarterly for patients with type 2 diabetes, whose A1C is not at target level (i.e. the eligibility criteria for this study sample).
3 secondary outcomes
Change in blood pressure
Time frame: Baseline, 6-months
Change in Low Density Lipoprotein (LDL)
Time frame: Baseline, 6-months
Change in Body Mass Index (BMI)
Time frame: Baseline, 6-months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: Yes. De-identified Individual Participant Data for the following measures will be restricted with a data use agreement: 1) Biometric and lab data including hemoglobin A1c, height, weight, body mass index, blood pressure, remote monitoring of blood glucose; 2) Demographics and health status per NIH required common data elements; 3) Survey assessment: Diabetes Distress Scale, Patient Health Questionnaire, Diabetes Self-Management Questionnaire, Diabetes Self-Efficacy, and Social Support
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PROMOTE and DSMES in people with Type 2 Diabetes, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Caroline Presley, MD (12059347609, capresley@uabmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Hemoglobin A1c (A1C) (time frame: Baseline, 6-months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.